Form 4: Insuleet Corp Executive Laetitia Cousin Reports Stock Transactions

Laetitia Cousin, SVP at Insulet Corp, reports acquisition of restricted stock units and stock options, as well as a disposition of shares to cover tax obligations.

Summary

• Laetitia Cousin, a Senior Vice President at Insulet Corp, filed a Form 4 detailing changes in beneficial ownership of the company's stock.
• On February 27, 2024, Cousin acquired 1,725 shares of common stock through a restricted stock unit (RSU) award.
• These RSUs vest in equal installments over three years.
• Also on February 27, 2024, Cousin was granted an option to purchase 4,132 shares of common stock at a price of $166.62, which becomes exercisable in equal installments over four years.
• On February 28, 2024, Cousin disposed of 62 shares of common stock at $163.6 to cover tax obligations related to the vesting of restricted stock units.
• Following these transactions, Cousin directly owns 3,109 shares of common stock and holds options for 4,132 shares.

Sentiment

Score: 6

Explanation: Neutral sentiment as the document primarily reports routine stock transactions related to executive compensation.

Positives

• The acquisition of RSUs and stock options suggests confidence in the company's future performance.

Negatives

• The disposal of shares to cover tax obligations, while routine, slightly reduces Cousin's direct shareholding.

Risks

• There are no specific risks highlighted in this document, as it primarily details stock transactions.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

This filing is a routine disclosure related to insider trading and provides limited insight into the broader industry context. It reflects standard compensation practices for executives in publicly traded companies.

Comparison to Industry Standards

• Stock option and RSU grants are common compensation tools for executives in the medical device industry, aligning with practices at companies like Medtronic, Abbott, and Boston Scientific.
• The vesting schedules described are typical, with RSUs vesting over 3 years and options over 4 years, similar to industry norms.

Stakeholder Impact

• The transactions have a minimal direct impact on stakeholders, as they are part of standard executive compensation practices.

Key Dates